Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals

BACKGROUND: The objective of this study was to investigate the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) during coronavirus disease 2019 (COVID-19) convalescence and after vaccination. METHODS: COVID-19-convalescent and -naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Luczkowiak, Joanna, Labiod, Nuria, Rivas, Gonzalo, Rolo, Marta, Lasala, Fátima, Lora-Tamayo, Jaime, Mancheno-Losa, Mikel, Rial, David, Pérez-Rivilla, Alfredo, Folgueira, María D, Delgado, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500154/
https://www.ncbi.nlm.nih.gov/pubmed/34642637
http://dx.doi.org/10.1093/ofid/ofab468
_version_ 1784580396371935232
author Luczkowiak, Joanna
Labiod, Nuria
Rivas, Gonzalo
Rolo, Marta
Lasala, Fátima
Lora-Tamayo, Jaime
Mancheno-Losa, Mikel
Rial, David
Pérez-Rivilla, Alfredo
Folgueira, María D
Delgado, Rafael
author_facet Luczkowiak, Joanna
Labiod, Nuria
Rivas, Gonzalo
Rolo, Marta
Lasala, Fátima
Lora-Tamayo, Jaime
Mancheno-Losa, Mikel
Rial, David
Pérez-Rivilla, Alfredo
Folgueira, María D
Delgado, Rafael
author_sort Luczkowiak, Joanna
collection PubMed
description BACKGROUND: The objective of this study was to investigate the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) during coronavirus disease 2019 (COVID-19) convalescence and after vaccination. METHODS: COVID-19-convalescent and -naïve individuals were tested for neutralizing activity against SARS-CoV-2 VoC Alpha, Beta, Gamma, and Delta at 1 and 7 months postinfection and 4–6 weeks after BNT162b2 vaccination. RESULTS: Vaccination induced a high neutralizing response in naïve individuals. Interestingly, vaccination of convalescent patients induced a boosted response that was able to neutralize all VoC at high titers. CONCLUSIONS: Vaccination with BNT162b2 induced high levels of neutralization against SARS-CoV-2 VoC in most patients; this is especially beneficial in COVID-19-convalescent individuals.
format Online
Article
Text
id pubmed-8500154
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85001542021-10-08 Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals Luczkowiak, Joanna Labiod, Nuria Rivas, Gonzalo Rolo, Marta Lasala, Fátima Lora-Tamayo, Jaime Mancheno-Losa, Mikel Rial, David Pérez-Rivilla, Alfredo Folgueira, María D Delgado, Rafael Open Forum Infect Dis Brief Report BACKGROUND: The objective of this study was to investigate the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) during coronavirus disease 2019 (COVID-19) convalescence and after vaccination. METHODS: COVID-19-convalescent and -naïve individuals were tested for neutralizing activity against SARS-CoV-2 VoC Alpha, Beta, Gamma, and Delta at 1 and 7 months postinfection and 4–6 weeks after BNT162b2 vaccination. RESULTS: Vaccination induced a high neutralizing response in naïve individuals. Interestingly, vaccination of convalescent patients induced a boosted response that was able to neutralize all VoC at high titers. CONCLUSIONS: Vaccination with BNT162b2 induced high levels of neutralization against SARS-CoV-2 VoC in most patients; this is especially beneficial in COVID-19-convalescent individuals. Oxford University Press 2021-09-24 /pmc/articles/PMC8500154/ /pubmed/34642637 http://dx.doi.org/10.1093/ofid/ofab468 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Luczkowiak, Joanna
Labiod, Nuria
Rivas, Gonzalo
Rolo, Marta
Lasala, Fátima
Lora-Tamayo, Jaime
Mancheno-Losa, Mikel
Rial, David
Pérez-Rivilla, Alfredo
Folgueira, María D
Delgado, Rafael
Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
title Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
title_full Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
title_fullStr Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
title_full_unstemmed Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
title_short Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
title_sort prime-boost vaccination with bnt162b2 induces high neutralizing activity against sars-cov-2 variants in naïve and covid-19-convalescent individuals
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500154/
https://www.ncbi.nlm.nih.gov/pubmed/34642637
http://dx.doi.org/10.1093/ofid/ofab468
work_keys_str_mv AT luczkowiakjoanna primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT labiodnuria primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT rivasgonzalo primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT rolomarta primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT lasalafatima primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT loratamayojaime primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT manchenolosamikel primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT rialdavid primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT perezrivillaalfredo primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT folgueiramariad primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals
AT delgadorafael primeboostvaccinationwithbnt162b2induceshighneutralizingactivityagainstsarscov2variantsinnaiveandcovid19convalescentindividuals

Ejemplares similares